Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€6.40

€6.40

-2.290%
-0.15
-2.290%
-

-

 
12.12.25 / Frankfurt WKN: A2PYCP / Name: Fortress Biotech Inc. / Stock / ? /

Fortress Biotech Inc. Stock

We can see a decrease in the price for Fortress Biotech Inc.. Compared to yesterday it has lost -€0.150 (-2.290%).
Our community identified positive and negative aspects for Fortress Biotech Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Fortress Biotech Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Fortress Biotech Inc. in the next few years

Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Fortress Biotech Inc. presents a rather intriguing financial narrative, marked by a mix of opportunities and challenges. While the company's revenue growth trajectory shows promise, especially with a 4.8% quarterly revenue increase year-over-year, several fundamental red flags deserve attention. The negative profit margins and persistently high losses indicate a need for strategic reassessment. Overall, Fortress Biotech's financials evoke a sense of cautious optimism tempered by considerable risk factors.

Revenue Growth: With a total revenue of approximately $85.1 million and a year-over-year revenue growth of 4.8%, Fortress Biotech is managing to expand its top line despite the broader operational challenges. This growth suggests that the company has the potential to capture market share or achieve sales traction with its products.

Book Value: The company boasts a book value of $1.188 per share, implying that it has some tangible asset backing for each share. This could serve as a safety net for investors, as it indicates a base level of value should the company restructure or liquidate in distress.